|
[posting]62742973[/posting]Nach den NPC Daten soll es direkt in die Phase 3 Studie übergehen .... Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol\u00ae Cyclo\u2122 for the Treatment of Niemann-Pick Disease Type C https://finance.yahoo.com/news/cyclo-therapeutics-announces-… Data from the current study combined with those of the companion Phase I study (ClinicalTrials.gov NCT02939547) will be used to inform the design of the Phase III global pivotal trial. Cyclo Therapeutics, Inc. will meet with FDA in the first quarter of 2020 and expects to meet with EMA in the second quarter of 2020 to discuss the global pivotal development plan and timelines to initiate the Phase III pivotal trial. |
|
| aus der Diskussion: | CTDH (MKap $20 M) NPC Daten in März/April ..Attraktiver Zock |
| Autor (Datum des Eintrages): | Biohero (20.02.20 22:35:40) |
| Beitrag: | 4 von 142 (ID:62743444) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |